Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.
Feuerstein graduated from Emory University with a bachelor's degree in political science.
Recent Articles By The Author
Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta
More about Vertex' Debbie Downer gene, Biogen's Alzheimer's spin and Sarepta caught in drug launch purgatory.
AstraZeneca Is Now a Competitive Threat to Tesaro in Ovarian Cancer Maintenance Therapy
AstraZeneca's Lynparza significantly delayed the recurrence of tumors in patients with ovarian cancer compared to a placebo, according to results from a phase III study announced by the company Wednesday.
Vertex Pharma Moves Next-Generation Cystic Fibrosis Drugs Into New Clinical Trials
Vertex hopes the new drugs will improve on the efficacy and tolerability of Orkambi, the first combination therapy approved for cystic fibrosis in 2015.
Bear Thesis on Corbus Pharma Could Cause a Crash Landing for High-Flying Biotech Stock
The market is acting like resunab is a real drug, which is why my investor source is short Corbus.
Global Blood, FDA Reach Agreement on Pivotal Trial Design for Sickle Cell Disease Drug
Global Blood wants to start screening sickle cell disease patients for the phase III study in December with the hope of having top-line results in the first half of 2019.